Please login to the form below

Not currently logged in


This page shows the latest ALN-PCS news and features for those working in and with pharma, biotech and healthcare.

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS

Alnylam predicts big things for its PCSK9 inhibitor ALN-PCS. Genesilencing specialist says its early-stage candidate has blockbuster potential. ... The success in the ongoing phase I trial means that clinical development of ALN-PCS is now taken over by

Latest news

  • Sanofi and Regeneron start cholesterol antibody trials

    Alnylam Pharmaceuticals is now thought to be in the lead among companies trying the antisense route to PCSK9 inhibition, with a successful phase I trial of its ALN-PCS candidate reported

  • Alnylam makes further cuts to workforce

    That involves accelerating the clinical development of the company's two lead programmes - ALN-TTR for the treatment of transthyretin-mediated amyloidosis and ALN-APC for haemophilia, which are both in ... Alnylam has also recently reported progress with

  • Alnylam says gene silencing therapy works for high cholesterol

    Alnylam says gene silencing therapy works for high cholesterol. ALN-PCS trial data contributes to restored interest in RNA interference. ... Alnylam Pharmaceuticals has reported encouraging results from a phase I trial of ALN-PCS, a gene silencing

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...